While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype





Skype Me™! 
 



 
 
 
 

PACLITAXEL TEVA
Home >> Search Drug By Letter >> Search Drug By Letter: P >> PACLITAXEL TEVA
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

PACLITAXEL TEVA
 
Package(a):
VIAL (concentrate for solution for infusion): 1 x 10 ml.
Dosage(a):
IV infusion administration. For adults only.
The recommended dose in adjuvant setting is 85 mg/m2 repeated every 2 weeks for 12 cycles (6 months).
Treatment of metastatic colorectal cancer: 85 mg/m2 repeated every 2 weeks.
To be administered as a 2-6 hour IV infusion in 5% glucose solution. See literature.
Mainly used in combination with continuous infusion 5-fluorouracil (5-FU) based regimens.
Renal impairment: In moderate renal impairment, treatment may be initiated at the normally recommended dose. There is no need for dose adjustment in patients with mild renal dysfunction. Has not been studied in patients with severe renal impairment.
Hepatic impairment: During clinical development no specific dose adjustments for patients with abnormal liver function were performed.
Elderly patients: No specific dose adjustments are required for the elderly.
Should always be administered before fluoropyrimidines.
See literature.

Prescribing Restrictions:  None

Package(b):
VIAL (concentrate for solution for infusion): 1 x 20 ml.
Dosage(b):
IV infusion administration. For adults only.
The recommended dose in adjuvant setting is 85 mg/m2 repeated every 2 weeks for 12 cycles (6 months).
Treatment of metastatic colorectal cancer: 85 mg/m2 repeated every 2 weeks.
To be administered as a 2-6 hour IV infusion in 5% glucose solution. See literature.
Mainly used in combination with continuous infusion 5-fluorouracil (5-FU) based regimens.
Renal impairment: In moderate renal impairment, treatment may be initiated at the normally recommended dose. There is no need for dose adjustment in patients with mild renal dysfunction. Has not been studied in patients with severe renal impairment.
Hepatic impairment: During clinical development no specific dose adjustments for patients with abnormal liver function were performed.
Elderly patients: No specific dose adjustments are required for the elderly.
Should always be administered before fluoropyrimidines.
See literature.

Prescribing Restrictions:  None


Indications:
In combination with 5-fluorouracil (5-FU) and folinic acid (FA) for: Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor; treatment of metastatic colorectal cancer.
Contra-Indications:
Hypersensitivity to oxaliplatin or to any of the excipients. Lactation. Patients with a peripheral sensitive neuropathy with functional impairment prior to first course. Myelosuppression prior to starting first course, as evidenced by baseline neutrophils <2 x 109/l and/or platelet count of <100 x 109/l. Patients with severely impaired renal function (creatinine clearance less than 30 ml/min).
Special Precautions:
Please contact distributing company for full details.
Side Effects:
Please contact distributing company for full details.
Drug Interactions:
Please contact distributing company for full details.